Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 238Carcinoma, Non-Small-Cell Lung 205Prostatic Neoplasms 137Lung Neoplasms 96Stomach Neoplasms 85Head and Neck Neoplasms 59Squamous Cell Carcinoma of Head and Neck 58Neoplasms 42Neoplasm Metastasis 39Esophageal Neoplasms 36Ovarian Neoplasms 29Pancreatic Neoplasms 27Sarcoma 19Urinary Bladder Neoplasms 18Adenocarcinoma of Lung 18Carcinoma, Squamous Cell 17Triple Negative Breast Neoplasms 15Nasopharyngeal Carcinoma 14Adenocarcinoma 14Carcinoma, Ovarian Epithelial 13Adenocarcinoma Of Esophagus 13Recurrence 12Inflammatory Breast Neoplasms 10Carcinoma, Transitional Cell 10Breast Neoplasms, Male 10Esophageal Squamous Cell Carcinoma 9Laryngeal Neoplasms 8Uterine Cervical Neoplasms 7Nasopharyngeal Neoplasms 7Leiomyosarcoma 7

Interventions

Androgen Antagonists 2relugolix 1niraparib 1Prednisone 1Docetaxel 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Hormone-sensitive Prostate Cancer (mHSPC) × Docetaxel × Clear all
NCT06392841 2026-04-08

HARMONY

Hoosier Cancer Research Network

Phase 2 Withdrawn
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡